PCM
SNDX icon

Penserra Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Penserra Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,115
Closed -$21K – 1535
2021
Q3 		$21K Buy
1,115
+15
+1% +$250 ﹤0.01% 1239
2021
Q2 		$18K Buy
1,100
+35
+3% +$641 ﹤0.01% 1175
2021
Q1 		$23K Buy
1,065
+125
+13% +$2.82K ﹤0.01% 953
2020
Q4 		$20K Buy
+940
New +$19.5K ﹤0.01% 849

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Penserra Capital Management's SNDX Position: Q4 2021 in Review

Penserra Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2021, closing a stake of 1,115 shares — an estimated $21K sold.

Penserra Capital Management first reported a position in SNDX in Q4 2020 and held it in 4 quarters. The position peaked at $23K in Q1 2021. 132 funds tracked by Wall St. Rank hold SNDX as of Q4 2021.

  • Penserra Capital Management reported no remaining Syndax Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,115 Syndax Pharmaceuticals shares in Q4 2021, an estimated $21K.
  • Penserra Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Syndax Pharmaceuticals position peaked at $23K in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.